Mavyret 100 mg/1 (Glecaprevir and Pibrentasvir TABLET, FILM COATED) 100 mg/1

Mavyret 100 mg/1 is a combination medication used for treating certain types of viral infections. This oral tablet contains Glecaprevir and Pibrentasvir, designed for convenient administration.

Strength

100 mg/1

Pack Size

4 CARTON in 1 CARTON (0074-2625-04) / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PAC

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mavyret 100 mg/1 is primarily used for the treatment of chronic hepatitis C virus (HCV) infection. This medication is often prescribed for adults with specific genotypes of HCV. Patients may wonder, 'What is Mavyret used for?' It is typically used as part of a comprehensive treatment plan to manage and reduce the viral load in the body.

Side Effects

Common effects of Mavyret 100 mg/1 may include fatigue, headache, and nausea. Some individuals might experience mild gastrointestinal discomfort. These effects can vary from person to person and are not experienced by everyone who takes the medication.

Precautions & Warnings

Mavyret 100 mg/1 should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients with liver conditions or other pre-existing health issues should discuss their medical history with their healthcare provider before starting this medication.

Avoid Interactions

Mavyret 100 mg/1 may interact with certain medications, including those metabolized by the liver. It is advisable to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.

References

Frequently Asked Questions

Mavyret 100 mg/1 is used for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Mavyret 100 mg/1 is taken orally, typically as directed by a healthcare professional.

Common side effects may include fatigue, headache, and nausea.

Mavyret may interact with certain medications, so it is important to consult a healthcare provider before combining it with other treatments.

Patients with liver conditions should discuss their medical history with a healthcare provider before taking Mavyret.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.